Brookside Capital Partners is pleased to announce its investment in ToxStrategies, LLC (“ToxStrategies”).
Founded in 2008 and headquartered in Katy, TX, ToxStrategies is a multidisciplinary scientific consulting firm that develops solutions to address complex regulatory, scientific, and technical challenges with an expertise in toxicology and epidemiology as it pertains to new and existing consumer-facing products. ToxStrategies provides its services through five practice areas pharmaceutical, health sciences, epidemiology, food and consumer products, and exposure sciences.
Brookside Capital Partners provided financing to support ToxStrategies’ add-on acquisition of Suttons Creek, LLC, a leading pharmaceutical combination products consulting and outsourcing business focused on the drug device value chain. ToxStrategies is a portfolio company of Renovus Capital Partners, a lower middle-market private equity firm, based in the Philadelphia area, specializing in the Knowledge and Talent industries.
About Brookside Capital Partners
Brookside has invested $1.3 billion since its founding in 2001. We are a leading provider of flexible capital solutions to lower middle-market companies, typically in the form of subordinated debt, unitranche loans and minority equity co-investments. Brookside generally invests $5 million to $30 million per transaction and has the resources to complete larger transactions, as well, by partnering with limited partners and associates. As a firm, we believe in partnership, collaboration, and achieving results together. We value the relationships with our sponsor and management partners and seek to find credit solutions that work for each unique situation. We deliver on our promises.
Please contact us or visit our website at brooksidecp.com for additional information. We welcome investment proposals and promise a prompt and confidential response.